The purpose of this study is to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability between RLD2202 and RLD2203 in healthy adult subjects
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Seoul National University Hospital
Seoul, South Korea
Cmax,ss of RLD2202
Pharmacokinetic evaluation
Time frame: 0~24 hours
AUCtau,ss of RLD2202
Pharmacokinetic evaluation
Time frame: 0~24 hours
Cmax,ss of RLD2203
Pharmacokinetic evaluation
Time frame: 0~24 hours
AUCtau,ss of RLD2203
Pharmacokinetic evaluation
Time frame: 0~24 hours
Inhibition of Platelet Aggregation(%)
Pharmacodynamic evaluation
Time frame: 0~6 days
Inhibition of Thromboxane B2(%)
Pharmacodynamic evaluation
Time frame: 0~6 days
Tmax,ss of RLD2202 and RLD2203
Pharmacokinetic evaluation
Time frame: 0~24 hours
t1/2,ss of RLD2202 and RLD2203
Pharmacokinetic evaluation
Time frame: 0~24 hours
Cmin,ss of RLD2202 and RLD2203
Pharmacokinetic evaluation
Time frame: 0~24 hours
Cavg,ss of RLD2202 and RLD2203
Pharmacokinetic evaluation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 0~24 hours
CLss/F of RLD2202 and RLD2203
Pharmacokinetic evaluation
Time frame: 0~24 hours
Vdss/F of RLD2202 and RLD2203
Pharmacokinetic evaluation
Time frame: 0~24 hours
PTF of RLD2202 and RLD2203
Pharmacokinetic evaluation
Time frame: 0~24 hours